Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug delivery platforms, this morning announced that it has
reached a definitive agreement to provide its patented DehydraTECH(TM)
technology to Cannadips CBD, the Original Smokeless CBD Dip Brand. According to
the update, each tin of Cannadips contains 15 pouches, each with 10mg of
hemp-derived CBD, and includes only natural sweeteners with no tobacco or
nicotine. Already established as the leader in CBD oral delivery, Lexaria has
been working behind the scenes with the Boldt Runners team to elevate the
product experience. “In our quest to create the ultimate smokeless, oral
cannabinoid experience for our customers, we found that the DehydraTECH
technology solves many challenges and propels the product forward as we pioneer
this product category,” The Boldt Runners Corporation Founder and Chief
Executive Officer Case Mandel said in the news release. “Through our
strong distribution partnership with Kretek International, and our family of
strategic retail partners including Sheetz, Kwiktrip, and Circle K we are
stoked for the DehydraTECH technology to shine through our tins.”
To view the full press release, visit http://ibn.fm/Z7H1l
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For more
information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment